Contraceptive applications of progesterone receptor modulators.
Currently developed progesterone receptor modulators (PRMs) are steroid-derived compounds with mild or potent antiprogestin activity. PRMs may exert a contraceptive activity by different mechanisms such as blockade of ovulation and endometrial desynchronization. Their potential clinical applications are manifold and are very promising in major public health areas, including emergency contraception, long term oestrogen-free contraception (administered alone, or in association with a progestin-only pill to improve bleeding patterns), endometriosis and myoma treatment. The mechanisms of their anti-ovulatory effects and of the endometrial modifications elicited during long term PRM treatment are still not fully elucidated. In future clinical applications, PRMs will be administered orally, via intrauterine systems or vaginal rings.
Chabbert-Buffet
Nathalie
N
Obstetrics and Gynaecology Unit, Hopital Tenon AP-HP, Paris, France. nathalie.chabbert-buffet@tnn.aphp.fr
Ouzounian
Sophie
S
Kairis
Axelle Pintiaux
AP
Bouchard
Philippe
P
D003271:Contraceptive Agents, Female / Q000494:pharmacology; D003278:Contraceptives, Oral, Hormonal / Q000494:pharmacology*; D003280:Contraceptives, Oral, Synthetic / Q000494:pharmacology; D003281:Contraceptives, Postcoital / Q000494:pharmacology*; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000494:pharmacology; D010060:Ovulation / Q000187:drug effects; D011980:Receptors, Progesterone / Q000187:drug effects*; D014592:Uterine Hemorrhage / Q000209:etiology
D003271:Contraceptive Agents, Female; D003278:Contraceptives, Oral, Hormonal; D003280:Contraceptives, Oral, Synthetic; D003281:Contraceptives, Postcoital; D011980:Receptors, Progesterone; D015735:Mifepristone